Advanced Solid Tumors (Including GCTTS) Clinical Trial
Official title:
An Exploratory Clinical Study to Evaluate the Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of BC006 Monoclonal Antibody Injection in Patients With Advanced Solid Tumors Including Giant Cell Tumor of Tendon Sheath
This is a first in human, open-label, exploratory phase I clinical study including dose escalation (Ia) and dose expansion (Ib) stage. It aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BC006 in giant cell tumor of tendon sheath (GCTTS) and other advanced solid tumors.
n/a
NCT number | NCT05212896 |
Study type | Interventional |
Source | Dragonboat Biopharmaceutical Company Limited |
Contact | Yuan Peng |
Phone | #86#021-50276381 |
[email protected] | |
Status | Recruiting |
Phase | Phase 1 |
Start date | November 26, 2021 |
Completion date | December 2024 |